189 related articles for article (PubMed ID: 26906063)
41. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
42. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.
Duxbury B; Combescure C; Chizzolini C
Lupus; 2013 Dec; 22(14):1489-503. PubMed ID: 24135078
[TBL] [Abstract][Full Text] [Related]
43. Exploring new territory: considering the future.
Schneider M
Lupus; 2007; 16(3):221-6. PubMed ID: 17432111
[TBL] [Abstract][Full Text] [Related]
44. Belimumab after rituximab as maintenance therapy in lupus nephritis.
Kraaij T; Huizinga TW; Rabelink TJ; Teng YK
Rheumatology (Oxford); 2014 Nov; 53(11):2122-4. PubMed ID: 25205827
[No Abstract] [Full Text] [Related]
45. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Rovin BH; Furie R; Latinis K; Looney RJ; Fervenza FC; Sanchez-Guerrero J; Maciuca R; Zhang D; Garg JP; Brunetta P; Appel G;
Arthritis Rheum; 2012 Apr; 64(4):1215-26. PubMed ID: 22231479
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.
Iwata S; Saito K; Hirata S; Ohkubo N; Nakayamada S; Nakano K; Hanami K; Kubo S; Miyagawa I; Yoshikawa M; Miyazaki Y; Yoshinari H; Tanaka Y
Lupus; 2018 Apr; 27(5):802-811. PubMed ID: 29308726
[TBL] [Abstract][Full Text] [Related]
47. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study.
Moroni G; Gallelli B; Sinico RA; Romano G; Sinigaglia L; Messa P
Ann Rheum Dis; 2012 Oct; 71(10):1751-2. PubMed ID: 22586177
[No Abstract] [Full Text] [Related]
48. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
Sfikakis PP; Boletis JN; Lionaki S; Vigklis V; Fragiadaki KG; Iniotaki A; Moutsopoulos HM
Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
[TBL] [Abstract][Full Text] [Related]
49. Failure of rituximab to treat a lupus flare-up with nephritis.
Lambotte O; Dürbach A; Kotb R; Ferlicot S; Delfraissy JF; Goujard C
Clin Nephrol; 2005 Jul; 64(1):73-7. PubMed ID: 16047649
[TBL] [Abstract][Full Text] [Related]
50. Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patients-a potential biomarker of disease activity.
Stratigou V; Doyle AF; Carlucci F; Stephens L; Foschi V; Castelli M; McKenna N; Cook HT; Lightstone L; Cairns TD; Pickering MC; Botto M
Rheumatology (Oxford); 2017 Jul; 56(7):1206-1216. PubMed ID: 28387859
[TBL] [Abstract][Full Text] [Related]
51. Analysis of HLA-G expression in renal tissue in lupus nephritis: a pilot study.
Foschi V; Bortolotti D; Doyle AF; Stratigou V; Stephens L; Trivedi P; Rinaldi R; Padovan M; Bortoluzzi A; Lightstone L; Cairns TD; Botto M; Cook TH; Rizzo R; Govoni M; Pickering MC
Lupus; 2019 Aug; 28(9):1091-1100. PubMed ID: 31291846
[TBL] [Abstract][Full Text] [Related]
52. Rituximab-refractory lupus nephritis successfully treated with belimumab.
Gonzalez-Echavarri C; Ugarte A; Ruiz-Irastorza G
Clin Exp Rheumatol; 2016; 34(2):355-6. PubMed ID: 26886714
[No Abstract] [Full Text] [Related]
53. Rituximab therapy in lupus nephritis: current clinical evidence.
Ramos-Casals M; Diaz-Lagares C; Soto-Cardenas MJ; Brito-Zeron P; Cuadrado MJ; Sanna G; Bertolaccini L; Khamashta MA
Clin Rev Allergy Immunol; 2011 Jun; 40(3):159-69. PubMed ID: 20419398
[TBL] [Abstract][Full Text] [Related]
54. [Antiphospholipid syndrome and lupus nephritis treated with rituximab].
Fraga G; Ballarín J; Jiménez I; Díaz M; Arce Y; Rodríguez JI; Cubells J
Nefrologia; 2007; 27(5):560-4. PubMed ID: 18045031
[No Abstract] [Full Text] [Related]
55. Remission of refractory lupus nephritis with a protocol including rituximab.
Fra GP; Avanzi GC; Bartoli E
Lupus; 2003; 12(10):783-7. PubMed ID: 14596429
[TBL] [Abstract][Full Text] [Related]
56. Use of rituximab in paediatric nephrology.
Sinha R; Agrawal N; Xue Y; Chanchlani R; Pradhan S; Raina R; Marks SD
Arch Dis Child; 2021 Nov; 106(11):1058-1065. PubMed ID: 34112638
[TBL] [Abstract][Full Text] [Related]
57. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
[TBL] [Abstract][Full Text] [Related]
58. Update on the treatment of lupus nephritis.
Waldman M; Appel GB
Kidney Int; 2006 Oct; 70(8):1403-12. PubMed ID: 16929249
[TBL] [Abstract][Full Text] [Related]
59. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
Li EK; Tam LS; Zhu TY; Li M; Kwok CL; Li TK; Leung YY; Wong KC; Szeto CC
Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041
[TBL] [Abstract][Full Text] [Related]
60. Acanthamoeba encephalitis in a patient with systemic lupus treated with rituximab.
Alkhunaizi AM; Dawamneh MF; Banda RW; Daabil RA; Al-Tawfiq JA; Akkad SA; Boukhamseen AH
Diagn Microbiol Infect Dis; 2013 Feb; 75(2):192-4. PubMed ID: 23265295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
